Biocon recently unveiled three new biosimilar oncology assets to its R&D pipeline —trastuzumab/hyaluronidase (Herceptin ...

Biocon Biologics has successfully simplified its capital structure, leading to an upgrade in its ratings by S&P Global. By ...

Biocon has completed the acquisition of the remaining equity shares of its unlisted subsidiary Biocon Biologics from Mylan ...

Pharma major Biocon is set to announce its Q3FY26 results on 12 Feb 2026. Brokerage reports project a strong Q3FY26 for Biocon, driven by robust momentum across biosimilars and generics.

BENGALURU, India and BRIDGEWATER, N.J., Oct. 1, 2025 /PRNewswire/ -- Biocon Biologics Ltd. (BBL), a fully integrated global biosimilars company and subsidiary of Biocon Ltd. (BSE: 532523, NSE: BIOCON) ...

Biocon Biologics has reached a settlement and license agreement with Regeneron that clears the way to commercialize Yesafili (aflibercept-jbvf), an interchangeable biosimilar aflibercept, in the ...

BRIDGEWATER, N.J., United States and BENGALURU, Karnataka, India, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Biocon Biologics Ltd. (BBL), a fully integrated global biosimilars ...

S&P Global Ratings has upgraded the long-term issuer credit rating of Biocon Biologics Limited to 'BB+' from 'BB' and revised ...

Receives a $2 Billion Cash Payment and $1 Billion of Convertible Preferred Equity Representing a Stake of at Least 12.9% (on a Fully Diluted Basis) in Biocon Biologics Marks the First in a Series of ...

BRIDGEWATER, N.J. and BENGALURU, India, Oct. 16, 2025 /PRNewswire/ -- Biocon Biologics Ltd. (BBL), a fully integrated global biosimilars company and subsidiary of Biocon Ltd. (BSE code: 532523, NSE: ...